JOINT FILING AGREEMENTJoint Filing Agreement • November 28th, 2017 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the 10.50% Series E Convertible Preferred Stock, $0.001 par value per share, of Peregrine Pharmaceuticals, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
SETTLEMENT AGREEMENTSettlement Agreement • November 28th, 2017 • Stafford John S Iii • Pharmaceutical preparations • Delaware
JOINDER AGREEMENTJoinder Agreement • October 27th, 2017 • Stafford John S Iii • Pharmaceutical preparations
This JOINDER AGREEMENT (the “Joinder”) is dated as of October 25, 2017 by and among Ronin Trading, LLC, John S. Stafford, III, SWIM Partners LP, SW Investment Management LLC, Stephen White, Roger Farley, James J. Egan, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian (collectively, the “Existing Members”) and Richard B. Hancock (the “New Member”).
JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2017 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Xencor, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
JOINDER AGREEMENTJoinder Agreement • October 17th, 2017 • Stafford John S Iii • Pharmaceutical preparations
This JOINDER AGREEMENT (the “Joinder”) is dated as of October 13, 2017 by and among Ronin Trading, LLC, John S. Stafford, III, SWIM Partners LP, SW Investment Management LLC, Stephen White, James J. Egan, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian (collectively, the “Existing Members”) and Roger Farley (the “New Member”).
JOINT FILING AGREEMENTJoint Filing Agreement • April 17th, 2018 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Statements on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.001 par value per share, and the 10.50% Series E Convertible Preferred Stock, $0.001 par value per share, of Avid Bioservices, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statements.
JOINT FILING AGREEMENTJoint Filing Agreement • December 1st, 2015 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Xencor, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
JOINDER AGREEMENTJoinder Agreement • October 17th, 2017 • Stafford John S Iii • Pharmaceutical preparations
This JOINDER AGREEMENT (the “Joinder”) is dated as of October 13, 2017 by and among Ronin Trading, LLC, John S. Stafford, III, SWIM Partners LP, SW Investment Management LLC, Stephen White, James J. Egan, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian (collectively, the “Existing Members”) and Roger Farley (the “New Member”).
JOINDER AGREEMENTJoinder Agreement • October 27th, 2017 • Stafford John S Iii • Pharmaceutical preparations
This JOINDER AGREEMENT (the “Joinder”) is dated as of October 26, 2017 by and among Ronin Trading, LLC, John S. Stafford, III, SWIM Partners LP, SW Investment Management LLC, Stephen White, Roger Farley, James J. Egan, Richard B. Hancock, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian (collectively, the “Existing Members”) and Joel McComb (the “New Member”).
JOINT FILING AGREEMENTJoint Filing Agreement • November 28th, 2017 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, $0.001 par value per share, of Peregrine Pharmaceuticals, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINDER AGREEMENTJoinder Agreement • October 11th, 2017 • Stafford John S Iii • Pharmaceutical preparations
This JOINDER AGREEMENT (the “Joinder”) is dated as of October 9, 2017 by and among Ronin Trading, LLC, John S. Stafford, III, SWIM Partners LP, SW Investment Management LLC, Stephen White, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian (collectively, the “Existing Members”) and James J. Egan (the “New Member”).
JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • July 14th, 2017 • Stafford John S Iii • Pharmaceutical preparations • New York
WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Peregrine Pharmaceuticals, Inc., a Delaware corporation (the “Company”);
JOINT FILING AGREEMENTJoint Filing Agreement • June 20th, 2014 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Xencor, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
